Nihon Kohden Corporation (NHNKY)
OTCMKTS · Delayed Price · Currency is USD
11.91
+0.69 (6.15%)
Feb 11, 2026, 3:59 PM EST
Nihon Kohden Revenue
Nihon Kohden had revenue of 55.89B JPY in the quarter ending December 31, 2025, with 0.36% growth. This brings the company's revenue in the last twelve months to 230.96B, up 2.97% year-over-year. In the fiscal year ending March 31, 2025, Nihon Kohden had annual revenue of 225.42B with 1.55% growth.
Revenue (ttm)
230.96B JPY
Revenue Growth
+2.97%
P/S Ratio
1.28
Revenue / Employee
37.78M JPY
Employees
6,114
Market Cap
1.88B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 225.42B | 3.44B | 1.55% |
| Mar 31, 2024 | 221.99B | 15.38B | 7.45% |
| Mar 31, 2023 | 206.60B | 1.47B | 0.72% |
| Mar 31, 2022 | 205.13B | 5.40B | 2.70% |
| Mar 31, 2021 | 199.73B | 14.72B | 7.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
Nihon Kohden News
- 2 months ago - Nihon Kohden Brings Advanced EEG Technology Built on 70 Years of Innovation to Booth #725 at the American Epilepsy Society 2025 Annual Meeting - Business Wire